Skip to main content
SpringerLink
Log in

Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?

  • Leading Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Interleukin-6 (IL-6) signaling is a critical target in inflammatory pathways. Today, tocilizumab (TCZ) and sarilumab (SAR), two IL-6 receptor-inhibiting monoclonal antibodies, are widely used in the treatment of rheumatoid arthritis (RA), with a favorable efficacy/safety profile. Successful introduction of such agents in the treatment of RA has encouraged the development of other agents targeting different points of the pathway. Sirukumab (SRK), a human anti-IL-6 monoclonal antibody, has been evaluated in clinical trials and showed largely similar clinical efficacy compared with TCZ and other IL-6 pathway-targeting agents. Furthermore, the drug safety profile seemed to reflect the profile of adverse effects and laboratory abnormalities seen in other inhibitors of the IL-6 pathway. However, increased death rates under SRK treatment compared with placebo raised safety concerns, which led to the decision by the FDA to decline the approval of SRK in August 2017. However, during the 18-week true placebo-controlled period, mortality rates were identical in the placebo- and SRK-treated patients. Comparisons after week 18 may be confounded by some factors, and also the ‘crossover’ design resulted in various treatment groups with varying drug exposure periods. The limited placebo exposure relative to SRK exposure makes interpretation of mortality rates difficult. We do not know whether the imbalance in mortality rates seen for SRK is a true safety signal or a result of bias due to the study design. Therefore, further long-term clinical data as well as basic research is needed to allow deeper insight into IL-6 signaling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford). 2018;57:ii43-ii50.

    Article  Google Scholar 

  2. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16:448–57.

    Article  CAS  PubMed  Google Scholar 

  3. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol. 2014;10:720–7.

    Article  CAS  PubMed  Google Scholar 

  4. Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141:125–39.

    Article  CAS  PubMed  Google Scholar 

  5. Hirano T. Revisiting the 1986 molecular cloning of interleukin 6. Front Immunol. 2014;5:456.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4(Suppl 3):S233–42.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013;19:822–4.

    Article  CAS  PubMed  Google Scholar 

  8. Bethin KE, Vogt SK, Muglia LJ. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA. 2000;97:9317–22.

    Article  CAS  PubMed  Google Scholar 

  9. Kraakman MJ, Kammoun HL, Allen TL, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015;21:403–16.

    Article  CAS  PubMed  Google Scholar 

  10. Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13:399–409.

    Article  CAS  PubMed  Google Scholar 

  11. Schaper F, Rose-John S. Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015;26:475–87.

    Article  CAS  PubMed  Google Scholar 

  12. Lehmann U, Schmitz J, Weissenbach M, et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem. 2003;278:661–71.

    Article  CAS  PubMed  Google Scholar 

  13. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58:573–81.

    Article  CAS  PubMed  Google Scholar 

  14. Mullberg J, Schooltink H, Stoyan T, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993;23:473–80.

    Article  CAS  PubMed  Google Scholar 

  15. Heink S, Yogev N, Garbers C, et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol. 2017;18:74–85.

    Article  CAS  PubMed  Google Scholar 

  16. Scheller J, Rose-John S. The interleukin 6 pathway and atherosclerosis. Lancet. 2012;380:338.

    Article  PubMed  Google Scholar 

  17. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol. 2014;26:2–12.

    Article  CAS  PubMed  Google Scholar 

  18. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121:3375–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rafiq S, Frayling TM, Murray A, et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun. 2007;8:552–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ferreira RC, Freitag DF, Cutler AJ, et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 2013;9:e1003444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jostock T, Mullberg J, Ozbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001;268:160–7.

    Article  CAS  PubMed  Google Scholar 

  22. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. 2000;6:583–8.

    Article  CAS  PubMed  Google Scholar 

  23. Hurst SM, Wilkinson TS, McLoughlin RM, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705–14.

    Article  CAS  PubMed  Google Scholar 

  24. Nowell MA, Richards PJ, Horiuchi S, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol. 2003;171:3202–9.

    Article  CAS  PubMed  Google Scholar 

  25. Mitsuyama K, Matsumoto S, Rose-John S, et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut. 2006;55:1263–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Nowell MA, Williams AS, Carty SA, et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol. 2009;182:613–22.

    Article  CAS  PubMed  Google Scholar 

  27. Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol. 2010;184:1543–51.

    Article  CAS  PubMed  Google Scholar 

  28. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491–501.

    Article  CAS  PubMed  Google Scholar 

  29. Doganci A, Eigenbrod T, Krug N, et al. The IL-6R alpha chain controls lung CD4 + CD25 + Treg development and function during allergic airway inflammation in vivo. J Clin Invest. 2005;115:313–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Hoge J, Yan I, Janner N, et al. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J Immunol. 2013;190:703–11.

    Article  CAS  PubMed  Google Scholar 

  31. Sodenkamp J, Waetzig GH, Scheller J, et al. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology. 2012;217:996–1004.

    Article  CAS  PubMed  Google Scholar 

  32. Safety and efficacy of TJ301 IV in participants with active ulcerative colitis. from https://clinicaltrials.gov/ct2/show/NCT03235752?cond=FE+999301&rank=1. Retrieved 27 May 2018.

  33. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol. 1992;19:22–5.

    CAS  PubMed  Google Scholar 

  34. Robak T, Gladalska A, Stepien H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 1998;7:347–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31:784–8.

    Article  CAS  PubMed  Google Scholar 

  36. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Straub RH, Muller-Ladner U, Lichtinger T, et al. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol. 1997;36:1298–303.

    Article  CAS  PubMed  Google Scholar 

  38. Atsumi T, Ishihara K, Kamimura D, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med. 2002;196:979–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Sasai M, Saeki Y, Ohshima S, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 1999;42:1635–43.

    Article  CAS  PubMed  Google Scholar 

  40. Hata H, Sakaguchi N, Yoshitomi H, et al. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 2004;114:582–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17:395–412.

    Article  CAS  PubMed  Google Scholar 

  42. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–8.

    Article  CAS  PubMed  Google Scholar 

  43. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42.

    Article  CAS  PubMed  Google Scholar 

  44. Briso EM, Dienz O, Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol. 2008;180:7102–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Dominitzki S, Fantini MC, Neufert C, et al. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4 + CD25 T cells. J Immunol. 2007;179:2041–5.

    Article  CAS  PubMed  Google Scholar 

  46. Thiolat A, Semerano L, Pers YM, et al. Interleukin-6 receptor blockade enhances CD39 + regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 2014;66:273–83.

    Article  CAS  PubMed  Google Scholar 

  47. Sirukumab Presentation to the Arthritis Advisory Committee August 2, 2017 Janssen R&D, LLC. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm570357.pdf. Retrieved 27 May 2018.

  48. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73:1616–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73:69–74.

    Article  CAS  PubMed  Google Scholar 

  50. Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:1653–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Abdallah H, Hsu JC, Lu P, et al. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017;57:459–68.

    Article  CAS  PubMed  Google Scholar 

  52. Enevold C, Baslund B, Linde L, et al. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics. 2014;24:401–5.

    CAS  PubMed  Google Scholar 

  53. Schuster B, Kovaleva M, Sun Y, et al. Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J Biol Chem. 2003;278:9528–35.

    Article  CAS  PubMed  Google Scholar 

  54. Garbers C, Spudy B, Aparicio-Siegmund S, et al. An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem. 2013;288:4346–54.

    Article  CAS  PubMed  Google Scholar 

  55. Miller RG, Bryan WW, Dietz MA, et al. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology. 1996;47:1329–31.

    Article  PubMed  Google Scholar 

  56. Petes C, Mintsopoulos V, Finnen RL, Banfield BW, Gee K: The effects of CD14 and IL-27 on induction of endotoxin tolerance in human monocytes and macrophages. J Biol Chem. 2018.

  57. Kalliolias GD, Gordon RA, Ivashkiv LB. Suppression of TNF-alpha and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27. J Immunol. 2010;185:7047–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Petes C, Mariani MK, Yang Y, Grandvaux N, Gee K. Interleukin (IL)-6 inhibits IL-27- and IL-30-mediated inflammatory responses in human monocytes. Front Immunol. 2018;9:256.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Zhang C, Xin H, Zhang W, et al. CD5 binds to interleukin-6 and induces a feed-forward loop with the transcription factor STAT3 in B cells to promote cancer. Immunity. 2016;44:913–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. McFarland-Mancini MM, Funk HM, Paluch AM, et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol. 2010;184:7219–28.

    Article  CAS  PubMed  Google Scholar 

  61. Lazzerini PE, Capecchi PL, Guidelli GM, et al. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. Drug Des Devel Ther. 2016;10:3083–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57.

    Article  CAS  PubMed  Google Scholar 

  63. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;52:2136–48.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Hsu B, Wang D, Sun Y, Chen G. Improvement in measures of depressed mood and anhedonia, and fatigue, in a randomized, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 antibody, in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):720–1. https://doi.org/10.1136/annrheumdis-2015-eular.4081.

    Article  Google Scholar 

  65. Zhou AJ, Lee Y, Salvadore G, et al. Sirukumab: a potential treatment for mood disorders? Adv Ther. 2017;34:78–90.

    Article  CAS  PubMed  Google Scholar 

  66. Choy EHS, Calabrese LH: Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). 2017.

  67. An efficacy and safety study of sirukumab in participants with major depressive disorder. https://clinicaltrials.gov/ct2/results?cond=&term=NCT02473289&cntry=&state=&city=&dist=. Retrieved 27 May 2018.

  68. Feaver R, Collado S, Hoang S, et al. The anti-IL-6 antibody sirukumab inhibits vascular inflammation in a human surrogate model of atherosclerosis. Abstract number: 439, ACR/ARHP annual meeting, 2014.

  69. Feaver R, Collado S, Hoang S, et al. Neutralization of IL6 by sirukumab (SIR) inhibits inflammation and cellular stress in a human vascular surrogate system of atherosclerosis. Ann Rheum Dis. 2015;74:444–5. https://doi.org/10.1136/annrheumdis-2015-eular.5132.

    Article  Google Scholar 

  70. Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013;65:2661–71.

    CAS  PubMed  Google Scholar 

  71. Rovin BH, van Vollenhoven RF, Aranow C, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol. 2016;68:2174–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96.

    Article  CAS  PubMed  Google Scholar 

  74. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75:1081–91.

    Article  CAS  PubMed  Google Scholar 

  75. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017;76:1279–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63:609–21.

    Article  CAS  PubMed  Google Scholar 

  77. Kremer JM, Blanco R, Halland AM, et al. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial. Clin Exp Rheumatol. 2016;34:625–33.

    PubMed  Google Scholar 

  78. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541–50.

    Article  CAS  PubMed  Google Scholar 

  79. Kim GW, Lee NR, Pi RH, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res. 2015;38:575–84.

    Article  CAS  PubMed  Google Scholar 

  80. Rafique A, Martin J, Blome M, Huang T, Ouyang A, Papadopoulos N. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (IL-6R) alpha. Ann Rheum Dis. 2013;72(Suppl3):797.

    Google Scholar 

  81. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73:1626–34.

    Article  CAS  PubMed  Google Scholar 

  82. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67:1424–37.

    Article  CAS  PubMed  Google Scholar 

  83. Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69:277–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840–7.

    Article  CAS  PubMed  Google Scholar 

  86. Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446–8.

    Article  CAS  PubMed  Google Scholar 

  88. Rissiek B, Koch-Nolte F, Magnus T. Nanobodies as modulators of inflammation: potential applications for acute brain injury. Front Cell Neurosci. 2014;8:344.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97.

    Article  CAS  PubMed  Google Scholar 

  90. Van Roy M, Ververken C, Beirnaert E, et al. The preclinical pharmacology of the high affinity anti-IL-6R nanobody(R) ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015;17:135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Holz JB, Sargentini-Maier L, De Bruyn S, Gachályi B, Udvaros I, Rojkovich B, Bruk S, Sramek P, Korkosz M, Krause K, Schoen P, D’Artois J, Verschueren K, Willems W, De Swert K, Arold G. Twenty-four weeks of treatment with a novel anti-IL-6 receptor nanobody® (aALX-0061) resulted in 84% ACR20 improvement and 58% DAS28 remission in a phase I/II study in RA. Ann Rheum Dis. 2013;72:A64.

  92. http://www.ablynx.com/rd-portfolio/clinical-programmes/vobarilizumab/. Retrieved 07 June 2018.

  93. Mayer CL, Xie L, Bandekar R, et al. Dose selection of siltuximab for multicentric Castleman’s disease. Cancer Chemother Pharmacol. 2015;75:1037–45.

    Article  CAS  PubMed  Google Scholar 

  94. van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15:966–74.

    Article  CAS  PubMed  Google Scholar 

  95. van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol. 2010;28:3701–8.

    Article  CAS  PubMed  Google Scholar 

  96. Sitenga J, Aird G, Ahmed A, Silberstein PT. Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease. Patient Relat Outcome Meas. 2018;9:35–41.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Finch DK, Sleeman MA, Moisan J, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011;411:791–807.

    Article  CAS  PubMed  Google Scholar 

  98. Study to assess the safety and tolerability of MEDI5117 in rheumatoid arthritis patients. https://clinicaltrials.gov/ct2/results?cond = &term = NCT01559103&cntry = &state = &city = &dist=. Retrieved 28 May 2018.

  99. Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012;71:1183–9.

    Article  CAS  PubMed  Google Scholar 

  100. Zhao Q, Pang J, Shuster D, Hung C, Baglino S, Dodge R, et al. Anti-IL-6 antibody clazakizumab is more potent than tocilizumab in blocking in vitro and ex vivo IL-6-induced functions (abstract). Arthritis Rheum. 2013;65(Suppl):S1020.

    Google Scholar 

  101. Weinblatt ME, Mease P, Mysler E, et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol. 2015;67:2591–600.

    Article  PubMed  Google Scholar 

  102. Kretsos K, Golor G, Jullion A, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: a randomized phase I study. Clin Pharmacol Drug Dev. 2014;3:388–95.

    Article  CAS  PubMed  Google Scholar 

  103. Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73:1607–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Genovese MC, Durez P, Fleischmann R, Tanaka Y, Furst DE, Yamanaka H, Vasyutin I, Kaviarasu T, Korneva E, Koloda D, Takeuchi T. Olokizumab treatment of both Western and Asian patients with rheumatoid arthritis who have failed anti-TNF treatment results in sustained improvements in patient-reported outcomes (abstract). Arthritis Rheumatol. 2016;68 :10.

    Google Scholar 

  105. Takeuchi T, Tanaka Y, Yamanaka H, et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial. Mod Rheumatol. 2016;26:15–23.

    Article  CAS  PubMed  Google Scholar 

  106. Evaluation of the effectiveness and safety of two dosing regimens of olokizumab (OKZ), compared to placebo, in subjects with rheumatoid arthritis (RA) who are taking an existing medication called a tumour necrosis factor alpha inhibitor but have active disease. https://clinicaltrials.gov/ct2/results?cond=&term = NCT02760433&cntry = &state = &city = &dist=. Retrieved 28 May 2018.

  107. Evaluation of the effectiveness and safety of two dosing regimens of olokizumab (OKZ), compared to placebo, in subjects with rheumatoid arthritis (RA) who are taking methotrexate but have active disease. from https://clinicaltrials.gov/ct2/results?cond=&term=NCT02760368&cntry=&state=&city=&dist=. Retrieved 28 May 2018.

  108. Evaluation of the effectiveness and safety of two dosing regimens of olokizumab (OKZ), compared to placebo and adalimumab, in subjects with rheumatoid arthritis (RA) who are taking methotrexate but have active disease. https://clinicaltrials.gov/ct2/results?cond=&term=NCT02760407&cntry=&state=&city=&dist=. Retrieved 28 May 2018.

  109. Evaluation of the long term safety, tolerability and efficacy of two dosing regimens of olokizumab (OKZ), in subjects with rheumatoid arthritis (RA) who previously completed 24 weeks of blinded treatment in one of the core studies—CREDO 1, 2 or 3. https://clinicaltrials.gov/ct2/results?cond=&term=NCT03120949&cntry=&state=&city=&dist=. Retrieved 28 May 2018.

  110. Genovese MC, Fleischmann R, Tanaka Y, Furst DE, Yamanaka H, Joshi R, Zhu W, Shao J, Mashimo H, Takeuchi T. Long-term safety and efficacy of olokizumab in patients with moderate-to-severe rheumatoid arthritis who have previously failed anti-TNF treatment. ACR/ARHP annual meeting, 2015.

  111. Open-label study to assess the safety and efficacy of CDP6038 in patients who completed RA0056. https://clinicaltrials.gov/ct2/show/NCT01296711?term=NCT01296711&rank=1. Retrieved 23 Oct 2018.

  112. The long-term safety and efficacy of olokizumab (CDP6038) with active rheumatoid arthritis. from https://clinicaltrials.gov/ct2/show/study/NCT01533714?term=NCT01533714&rank=1. Retrieved 23 Oct 2018.

  113. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Takeuchi T, Yamanaka H, Harigai M, et al. Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients. Arthritis Res Ther. 2018;20:42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Takeuchi T, Thorne C, Karpouzas G, et al. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis. 2017;76:2001–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Aletaha D, Bingham CO 3rd, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 2017;389:1206–17.

    Article  CAS  PubMed  Google Scholar 

  117. Taylor PC, Schiff MH, Wang Q, et al. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Ann Rheum Dis. 2018;77:658–66.

    Article  CAS  PubMed  Google Scholar 

  118. Long-term safety and efficacy of sirukumab in participants with RA completing studies CNTO136ARA3002 or CNTO136ARA3003. https://clinicaltrials.gov/ct2/results?cond=&term=NCT01856309&cntry=&state=&city=&dist=. Retrieved 29 May 2018.

  119. Food and Drug Administration, Center for drug evaluation and research, summary minutes of the arthritis advisory committee meeting, 2 August 2017. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm575678.pdf. Retrieved 29 May 2018.

  120. Arthritis Advisory Committee briefing document by Janssen Research & Development for Plivensia™ (sirukumab), 28 June 2017. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm569153.pdf. Retrieved 29 May 2018.

  121. Aletaha D, Thorne C, Schiff M, Harigai M, Agarwal P, Rao R, Cohen C, Cheng B, Brown K, Hsu B. Integrated phase 3 safety results of sirukumab, an anti-IL-6 cytokine monoclonal antibody, in patients with active rheumatoid arthritis (abstract). Arthritis Rheumatol. 2017; 69 (suppl 10). http://acrabstracts.org/abstract/integrated-phase-3-safety-results-of-sirukumab-an-anti-il-6-cytokine-monoclonal-antibody-in-patients-with-active-rheumatoid-arthritis/. Retrieved 27 May 2018.

  122. Withdrawal assessment report for Plivensia™ (sirukumab), 14 September 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2018/02/WC500243181.pdf. Retrieved 29 May 2018.

  123. Ogdie A, Haynes K, Troxel AB, et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis. 2014;73:149–53.

    Article  PubMed  Google Scholar 

  124. Sparks JA, Chang SC, Liao KP, et al. Rheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the Nurses’ Health Study. Arthritis Care Res (Hoboken). 2016;68:753–62.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Zhang Y, Lu N, Peloquin C, et al. Improved survival in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis. 2017;76:408–13.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Rheumatology, Life Hospital, Antalya, Turkey

    Ali Berkant Avci

  2. Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany

    Eugen Feist & Gerd Rüdiger Burmester

Authors
  1. Ali Berkant Avci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugen Feist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerd Rüdiger Burmester
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eugen Feist.

Ethics declarations

Conflict of Interest

GRB has received grants from Roche, including travel support, and has received consulting fees/payment for lectures from Roche, Sanofi, and Janssen. EF has received grants, consulting/speaker fees from Roche and Sanofi. ABA has received honoraria for lecturing from MSD.

Funding

No sources of funding were used to support the writing of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Avci, A.B., Feist, E. & Burmester, G.R. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?. BioDrugs 32, 531–546 (2018). https://doi.org/10.1007/s40259-018-0320-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-018-0320-3

Search

Navigation